A selective TP receptor antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SQ 29,548

Item No. 19025

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(5Z)-7-[(1S,2R,3R,4R)-3-[[2-[(phenylamino)carbonyl]hydrazinyl]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid
CAS Number
98672-91-4
Molecular Formula
C21H29N3O4
Formula Weight
387.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 0.2 mg/mlDMSO: 5 mg/mlEthanol: 0.5 mg/mlPBS pH 7.2: 0.25 mg/ml
SMILES
OC(=O)CCC/C=C\CC1C2CCC(O2)C1CNNC(=O)Nc1ccccc1
InChi Code
InChI=1S/C21H29N3O4/c25-20(26)11-7-2-1-6-10-16-17(19-13-12-18(16)28-19)14-22-24-21(27)23-15-8-4-3-5-9-15/h1,3-6,8-9,16-19,22H,2,7,10-14H2,(H,25,26)(H2,23,24,27)/b6-1-
InChi Key
RJNDVCNWVBWHLY-BHQIHCQQSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $94

    Add

    5 mg

    $422

    Add

    10 mg

    $748

    Add

    25 mg

    $1,403

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    SQ 29,548 is a highly selective TP receptor antagonist which binds to the human recombinant TP receptor with a Ki of 4.1 nM.1 It inhibits the aggregation of washed human platelets induced by U-46619 with an IC50 of 0.06 µM.2 It antagonizes U-46619 induced contraction of rat and guinea pig tracheal, arterial, and venous smooth muscles with drug/receptor dissociation constants (KB) in the range of 0.5-1.7 nM.3 SQ 29,548 also inhibits the contraction of rat vascular smooth muscle induced by 8-iso PGF2α.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483(2), 285-293 (2000).

    2. Ogletree, M.L., Harris, D.N., Greenberg, R., et al. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 234, 435-441 (1985).

    3. Ogletree, M.L., and Allen, G.T. Interspecies differences in thromboxane receptors: Studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J. Pharmacol. Exp. Ther. 260, 789-794 (1992).

    4. Fukunaga, M., Makita, N., Roberts, L.J., II, et al. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264, C1619-C1624 (1993).

    Product Citations

    Oestreich, J.H., Ferraris, S.P., Steinhubl, S.R., et al. Pharmacodynamic interplay of the P2Y1, P2Y12, and TXA2 pathways in platelets: The potential of triple antiplatelet therapy with P2Y1 receptor antagonism. Thromb. Res. 131(2), e64-e70 (2013).

    Opere, C.A., Zheng, W.D., Huang, J., et al. Dual effect of isoprostanes on the release of [3H]D-aspartate from isolated bovine retinae: Role of arachidonic acid metabolites. Neurochem. Res. 30(1), 129-137 (2005).

    Woodward, D.F., Krauss, A.H.P., Chen, J., et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305(2), 772-785 (2003).